Despite NYT Reporting Pfizer (PFE) Could Release COVID Efficacy Data in October - Morgan Stanley
Tweet Send to a Friend
Morgan Stanley analyst David Risinger reiterated an Equalweight rating and $42.00 price target on Pfizer (NYSE: PFE) after the New ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
